Clinical Trials Browser

Active not recruiting × Interventional × obinutuzumab × Clear all

NCT06073821 2026-04-16

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03269669 2026-04-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT03462719 2026-04-13

GLOW

Phase 3 Active not recruiting

211 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03701282 2026-04-13

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

465 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04450173 2026-04-13

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT05798156 2026-04-08

R-Pola-Glo

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04722172 2026-04-06

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02537613 2026-04-01

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04277637 2026-03-27

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Phase 1 Active not recruiting

Mature B-Cell Malignancies

NCT05896163 2026-03-27

MAPtivate-6

Phase 1/2 Active not recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02629809 2026-03-06

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT05057494 2026-02-18

MAJIC

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03580928 2026-02-13

AVO

Phase 2 Active not recruiting

72 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Phase 1/2 Active not recruiting

87 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06291220 2026-01-08

453 Ph1 CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04843904 2026-01-07

SAVE

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04447768 2025-10-14

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Phase 1 Active not recruiting

Part1: Advanced B-cell Malignancies

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

Phase 3 Active not recruiting

535 enrolled 19 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

23 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT04515238 2025-06-10

CLL2-BZAG

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT03322865 2025-04-04

Obinutuzumab in Marginal Zone Lymphoma

Phase 2 Active not recruiting

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT04962126 2025-03-21

FLUORO

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT04608318 2024-12-31

CLL17

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03836261 2024-12-27

AMPLIFY

Phase 3 Active not recruiting

984 enrolled 3 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06547944 2024-08-09

ZGR in TN CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03980171 2024-07-29

LEVERAGE

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT05387616 2024-03-12

Alternative-C

Phase 2 Active not recruiting

Lymphoma, Follicular